Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis
- PMID: 24004885
- DOI: 10.1016/j.jconrel.2013.08.021
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis
Abstract
Immunotherapy has shown the potential to become an essential component of the successful treatment of various malignancies. In many cases, such as in melanoma, however, induction of a potent and specific T-cell response against the endogenous antigen or self-antigen still remains a major challenge. To induce a potent MHC I-restricted cytotoxic T-lymphocyte (CTL) response, cytosol delivery of an exogenous antigen into dendritic cells is preferred, if not required. Lipid-calcium-phosphate (LCP) nanoparticles represent a new class of intracellular delivery systems for impermeable drugs. We are interested in exploring the potential of LCP NPs for use as a peptide vaccine delivery system for cancer therapy. To increase the encapsulation of Trp2 peptide into the calcium phosphate precipitate core of LCP, two phosphor-serine residues were added to the N-terminal of the peptide (p-Trp2). CpG ODN was also co-encapsulated with p-Trp2 as an adjuvant. The NPs were further modified with mannose to enhance and prolong the cargo deposit into the lymph nodes (LNs), which ensured persistent antigen loading and stimulation. Compared with free Trp2 peptide/CpG, vaccination with LCP encapsulating p-Trp2 and CpG resulted in superior inhibition of tumor growth in both B16F10 subcutaneous and lung metastasis models. An IFN-γ production assay and in vivo CTL response study revealed that the improved efficacy was a result of a Trp2-specific immune response. Thus, encapsulation of phospho-peptide antigens into LCP may be a promising strategy for enhancing the immunogenicity of poorly immunogenic self-antigens for cancer therapy.
Keywords: 1,2-dioleoyl-3-trimethylammonium-propane chloride salt; 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethyleneglycol-2000)] ammonium salt; APCs; CFSE; CTL; CaP; Calcium phosphate; DOPA; DOTAP; DSPE-PEG; Immunotherapy; MHC; Melanoma; Nanoparticle; Peptide vaccine; Trp2; antigen presenting cells; calcium phosphate; carboxyfluorescein succinimidyl ester; cytotoxic T lymphocyte; dioleoylphosphatydic acid; major histocompatibility complex; tyrosinase-related protein 2.
© 2013.
Similar articles
-
The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.Theranostics. 2018 Feb 12;8(6):1723-1739. doi: 10.7150/thno.22056. eCollection 2018. Theranostics. 2018. PMID: 29556352 Free PMC article.
-
Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.J Immunother. 2006 May-Jun;29(3):294-305. doi: 10.1097/01.cji.0000199195.97845.18. J Immunother. 2006. PMID: 16699372
-
Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.Int J Nanomedicine. 2020 Dec 1;15:9571-9586. doi: 10.2147/IJN.S275670. eCollection 2020. Int J Nanomedicine. 2020. PMID: 33293808 Free PMC article.
-
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43. doi: 10.1016/j.ejpb.2013.07.002. Epub 2013 Jul 17. Eur J Pharm Biopharm. 2013. PMID: 23872180 Review.
-
Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy.Hum Vaccin Immunother. 2013 Jun;9(6):1234-6. doi: 10.4161/hv.23990. Epub 2013 Feb 14. Hum Vaccin Immunother. 2013. PMID: 23411443 Free PMC article. Review.
Cited by
-
The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure.Bioact Mater. 2020 Sep 22;6(3):697-711. doi: 10.1016/j.bioactmat.2020.09.002. eCollection 2021 Mar. Bioact Mater. 2020. PMID: 33005832 Free PMC article.
-
Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma.Biomaterials. 2015 Nov;68:54-66. doi: 10.1016/j.biomaterials.2015.07.053. Epub 2015 Aug 1. Biomaterials. 2015. PMID: 26264646 Free PMC article.
-
Macrophage ghost entrapped amphotericin B: a novel delivery strategy towards experimental visceral leishmaniasis.Drug Deliv Transl Res. 2019 Feb;9(1):249-259. doi: 10.1007/s13346-018-00602-1. Drug Deliv Transl Res. 2019. PMID: 30430452
-
Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.Theranostics. 2018 Jun 13;8(14):3781-3796. doi: 10.7150/thno.24821. eCollection 2018. Theranostics. 2018. PMID: 30083259 Free PMC article.
-
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery.Nano Lett. 2014;14(4):2181-8. doi: 10.1021/nl500618u. Epub 2014 Mar 28. Nano Lett. 2014. PMID: 24673373 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous